Targeting the arginine metabolic brake enhances immunotherapy for leukaemia

Therapeutic approaches which aim to target Acute Myeloid Leukaemia through enhancement of patients’ immune responses have demonstrated limited efficacy to date, despite encouraging preclinical data. Examination of AML patients treated with azacitidine (AZA) and vorinostat (VOR) in a Phase II trial,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Int J Cancer
Main Authors: Mussai, Francis, Wheat, Rachel, Sarrou, Evgenia, Booth, Sarah, Stavrou, Victoria, Fultang, Livingstone, Perry, Tracey, Kearns, Pamela, Cheng, Paul, Keeshan, Karen, Craddock, Charles, De Santo, Carmela
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Inc. 2019
Assuntos:
Tumor Immunology and Microenvironment
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6767531/
https://ncbi.nlm.nih.gov/pubmed/30485425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32028
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares